Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot could help control blood sugar in type 2 diabetes

NCT ID NCT06354660

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new weekly medicine called retatrutide in 537 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either the medicine or a placebo for about 11 months. The goal was to see if retatrutide safely lowers blood sugar and helps with weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

537 people

The number who actually took part.

Started

Apr 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥ 7.0% to ≤ 9.5% * Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening * Are of stable weight for at least 90 days prior to screening * Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m\^2) Exclusion Criteria: * Have Type 1 Diabetes (T1D) * Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have an estimated glomerular filtration rate (eGFR) \<15 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) as determined by the central laboratory * Have a prior or planned surgical treatment for obesity * Have New York Heart Association Functional Classification IV congestive heart failure * Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening * Have a known clinically significant gastric emptying abnormality * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years * Have any lifetime history of a suicide attempt * Had chronic or acute pancreatitis * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2 * Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocrine system disorder glucose metabolism disease metabolic disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 2

Contacts and locations

Locations

  • Accellacare - Wilmington - 1917 Tradd Court

    Wilmington, North Carolina, 28401, United States

  • All India Institute of Medical Sciences

    Raipur, Chhattisgarh, 492099, India

  • All India Institute of Medical Sciences

    Bhubaneswar, Odisha, 751019, India

  • Ark Clinical Research

    Long Beach, California, 90815, United States

  • Arké SMO S.A de C.V

    Veracruz, 91910, Mexico

  • Boeson Research MSO

    Missoula, Montana, 59804, United States

  • Brij Medical Centre Private Limited

    Kanpur, Uttar Pradesh, 208020, India

  • Centro de investigación y control metabólico

    San Nicolás de los Garza, Nuevo León, 66465, Mexico

  • Clinical Research Associates Inc

    Nashville, Tennessee, 37203, United States

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • Clinical Research of Central Florida

    Winter Haven, Florida, 33880, United States

  • Clinical Research of Philadelphia

    Philadelphia, Pennsylvania, 19114, United States

  • Clínica García Flores SC

    Monterrey, Nuevo León, 64610, Mexico

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas, 66606, United States

  • Delricht Research - Tobias Gadson Boulevard - Charleston

    Charleston, South Carolina, 29407, United States

  • Dorado Medical Complex

    Dorado, 00646, Puerto Rico

  • EME RED Hospitalaria

    Mérida, Yucatán, 97000, Mexico

  • Eastside Research Associates

    Redmond, Washington, 98052, United States

  • Eternal Heart Care Center and Research Institute

    Jaipur, Rajasthan, 302020, India

  • Ezy Medical Research

    Miami, Florida, 33175, United States

  • Government Medical College - Kozhikode

    Kozhikode, Kerala, 673008, India

  • Grupo Ollin Care

    Pachuca, Hidalgo, 42000, Mexico

  • Gujarat Endocrin Pvt Ltd

    Ahmedabad, Gujarat, 380052, India

  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad

    Guadalajara, Jalisco, 04460, Mexico

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, Mexico City, 14080, Mexico

  • Lifedoc Research - Lenox Park Drive

    Memphis, Tennessee, 38115, United States

  • Manassas Clinical Research Center

    Manassas, Virginia, 20110, United States

  • Medical Care and Research SA de CV

    Mérida, Yucatán, 97070, Mexico

  • MultiCare Rockwood Cheney Clinic

    Cheney, Washington, 99004, United States

  • NECCR PrimaCare Research

    Fall River, Massachusetts, 02721, United States

  • NJ MedCare & NJ Heart

    Linden, New Jersey, 07036, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • Nirmal Hospital Pvt Ltd.

    Surat, Gujarat, 395002, India

  • Northeast Research Institute (NERI)

    Fleming Island, Florida, 32003, United States

  • Ponce Medical School Foundation Inc.

    Ponce, 00716, Puerto Rico

  • Preferred Primary Care Physicians

    Uniontown, Pennsylvania, 15401, United States

  • Prime Revival Research Institute, LLC

    Flower Mound, Texas, 75028, United States

  • Providence Health Partners-Center for Clinical Research

    Dayton, Ohio, 45439, United States

  • San Fernando Valley Health Institute

    Canoga Park, California, 91304, United States

  • Scottsdale Clinical Trials

    Scottsdale, Arizona, 85260, United States

  • Texas Valley Clinical Research

    Weslaco, Texas, 78596, United States

  • Trinity Research Centers

    Marietta, Georgia, 30064, United States

  • Tucson Clinical Research Institute

    Tucson, Arizona, 85712, United States

  • Unidad biomedica avanzada monterrey

    Monterrey, Nuevo León, 64460, Mexico

  • Valley Institute of Research - Fort Worth

    Fort Worth, Texas, 76164, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Victoria Hospital, Bangalore Medical College And Research Institute

    Bangalore, Karnataka, 560002, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.